Literature DB >> 20175026

Multicentric tumor manifestations of high grade gliomas: independent proliferation or hallmark of extensive disease?

Martin Hefti1, G von Campe, C Schneider, U Roelcke, H Landolt.   

Abstract

OBJECTIVE: Improvements in microneurosurgical techniques, radiotherapy and chemotherapy for the treatment of high grade gliomas resulted in better local tumor control and longer progression-free survival. Multicentric (MC) lesions located distant from the initial resection area contribute to treatment failure in a growing number of patients. These MC lesions may develop within the course of the disease (metachronous) or may already be present at the time of first tumor manifestation (synchronous). To look for mechanisms and regular patterns behind MC glioma manifestations and to investigate whether they are "a second primary tumor" or the result of continuous diffuse glioblastoma cell invasion, we retrospectively analyzed the initial and all follow-up MR studies of our high grade glioma (HGG) patients. PATIENTS AND METHODS: MR studies of 247 consecutive patients treated for HGG at a single institution were analyzed. MC tumor manifestation was defined as more than one gadolinium enhancing lesion within the brain on MRI without a connecting signal alteration in T2 sequences and/or without a connecting hypointense mass in T1 sequences. The minimal distance to define two solitary lesions was set at >10 mm. According to these specifications 40 patients showed MC tumor manifestations in their MR studies on admission or during treatment of their disease. The MR studies of these cases were retrospectively analyzed for patterns in MC tumor manifestation and progression. Topographical specifications and delay in manifestation were used to explain possible pathways of development. Kaplan Meyer survival graphs for metachronous and synchronous MC disease were calculated.
RESULTS: 24 patients showed MC tumor manifestation at the time of admission. 16 cases developed MC manifestation within a follow-up period of 3-57 months. The location of all lesions could be categorized into one of three distinct patterns (white matter, subependymal, intraventricular). The patterns showed individual and location-specific time gaps to metachronous manifestation. Calculated from the time of first tumor diagnosis, the median survival was longer for patients with metachronous MC lesions (353 days, p<0.05) compared to patients with synchronous MC lesions (110 days) or patients without multicentricity (234 days). Patients with metachronous lesions showed a similar survival (72 days) as patients with synchronous MC lesions (110 days) once they developed MC disease.
CONCLUSION: The topographical patterns and temporal characteristics of MC disease suggest that all manifestations share common mechanisms such as an active migratory process. Our data therefore do not support the concept of an independent MC development of multiple gliomas. Georg Thieme Verlag KG Stuttgart * New York.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20175026     DOI: 10.1055/s-0029-1241190

Source DB:  PubMed          Journal:  Cent Eur Neurosurg        ISSN: 1868-4904


  9 in total

1.  Malignant spinal cord compression in cerebral glioblastoma multiforme: a multicenter case series and review of the literature.

Authors:  Alexander Tinchon; Stefan Oberndorfer; Christine Marosi; Roberta Rudà; Cornelia Sax; Bernadette Calabek; Wolfgang Grisold
Journal:  J Neurooncol       Date:  2012-08-14       Impact factor: 4.130

2.  Gliomas of the posterior fossa in adults.

Authors:  Ido Strauss; Tali Jonas-Kimchi; Felix Bokstein; Deborah Blumenthal; Jonathan Roth; Razi Sitt; Jefferson Wilson; Zvi Ram
Journal:  J Neurooncol       Date:  2013-08-27       Impact factor: 4.130

3.  Integrative radiogenomic analysis for multicentric radiophenotype in glioblastoma.

Authors:  Doo-Sik Kong; Jinkuk Kim; In-Hee Lee; Sung Tae Kim; Ho Jun Seol; Jung-Il Lee; Woong-Yang Park; Gyuha Ryu; Zichen Wang; Avi Ma'ayan; Do-Hyun Nam
Journal:  Oncotarget       Date:  2016-03-08

4.  Efficacy, Outcome, and Safety of Elderly Patients with Glioblastoma in the 5-ALA Era: Single Center Experience of More Than 10 Years.

Authors:  Barbara Kiesel; Lisa I Wadiura; Mario Mischkulnig; Jessica Makolli; Veronika Sperl; Martin Borkovec; Julia Freund; Alexandra Lang; Matthias Millesi; Anna S Berghoff; Julia Furtner; Adelheid Woehrer; Georg Widhalm
Journal:  Cancers (Basel)       Date:  2021-12-04       Impact factor: 6.639

Review 5.  Multicentric Glioma: An Ideal Model to Reveal the Mechanism of Glioma.

Authors:  Yong Yan; Wei Dai; Qiyong Mei
Journal:  Front Oncol       Date:  2022-06-07       Impact factor: 5.738

6.  Synchronous multicentric glioblastoma with PNET and O subtypes: Possible pathogenesis.

Authors:  Kai Rui Wan; Nicolas K K King; Sharon Y Y Low; Yih-Yian Sitoh; Hwei Yee Lee; Chin Fong Wong; Wai Hoe Ng
Journal:  Surg Neurol Int       Date:  2014-03-04

7.  Factors associated with a higher rate of distant failure after primary treatment for glioblastoma.

Authors:  Sonia Tejada; Guillermo Aldave; Miguel Marigil; Jaime Gállego Pérez-Larraya; Jaime de Gallego; Pablo Daniel Domínguez; Ricardo Díez-Valle
Journal:  J Neurooncol       Date:  2013-10-18       Impact factor: 4.130

8.  Canine Butterfly Glioblastomas: A Neuroradiological Review.

Authors:  John H Rossmeisl; Kemba Clapp; Theresa E Pancotto; Samantha Emch; John L Robertson; Waldemar Debinski
Journal:  Front Vet Sci       Date:  2016-05-19

Review 9.  Multiple cerebral gliomas mimicking central nervous system inflammatory demyelinating diseases: A rare case with review of literature.

Authors:  Yong-Jie Xiong; Xin-Ling Zhao; Xiao-Yan Wang; Deng-Ji Pan; Dai-Shi Tian
Journal:  Medicine (Baltimore)       Date:  2017-12       Impact factor: 1.889

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.